Philippines - English - FDA (Food And Drug Administration)

panpharma-meinz pharmaceuticals corp. - cefoxitin - powder for injection - 1 g

Philippines - English - FDA (Food And Drug Administration)

panpharma meinz pharmaceuticals; distributor: panpharma meinz pharmaceuticals - cefotaxime (as sodium) - powder for injection (im/iv) - 1g

Philippines - English - FDA (Food And Drug Administration)

panpharma meinz pharmaceuticals; distributor: panpharma meinz pharmaceuticals - piperacillin (as sodium) , tazobactam (as sodium) - solution for infusion (iv) - 2g/ 250mg

Philippines - English - FDA (Food And Drug Administration)

panpharma meinz pharmaceuticals; distributor: panpharma meinz pharmaceuticals - piperacillin (as sodium) , tazobactam (as sodium) - solution for infusion - 4g/ 500mg

Australia - English - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - droperidol, quantity: 2.5 mg/ml - injection, solution - excipient ingredients: mannitol; tartaric acid; sodium hydroxide; nitrogen; water for injections - anaesthesia droperidol panpharma injection is indicated to produce tranquillisation and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures; for premedication, induction, and as an adjunct in the maintenance of general and regional anaesthesia; in neuroleptanalgesia in which droperidol panpharma injection is given concurrently with a narcotic analgesic, to aid in producing tranquillity and decreasing anxiety and pain.,psychiatry the management of severe agitation, hyperactivity, or aggressiveness in psychotic disorders, including schizophrenic reaction and the manic type of manic depressive illness, or in disturbed states, such as some types of acute brain syndrome and in nonpsychotic acute excitation states.

Australia - English - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - droperidol, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: mannitol; tartaric acid; sodium hydroxide; nitrogen; water for injections - anaesthesia droperidol panpharma injection is indicated to produce tranquillisation and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures; for premedication, induction, and as an adjunct in the maintenance of general and regional anaesthesia; in neuroleptanalgesia in which droperidol panpharma injection is given concurrently with a narcotic analgesic, to aid in producing tranquillity and decreasing anxiety and pain.,psychiatry the management of severe agitation, hyperactivity, or aggressiveness in psychotic disorders, including schizophrenic reaction and the manic type of manic depressive illness, or in disturbed states, such as some types of acute brain syndrome and in nonpsychotic acute excitation states.

Australia - English - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - droperidol, quantity: 2.5 mg/ml - injection, solution - excipient ingredients: mannitol; tartaric acid; sodium hydroxide; nitrogen; water for injections - anaesthesia droperidol panpharma injection is indicated to produce tranquillisation and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures; for premedication, induction, and as an adjunct in the maintenance of general and regional anaesthesia; in neuroleptanalgesia in which droperidol panpharma injection is given concurrently with a narcotic analgesic, to aid in producing tranquillity and decreasing anxiety and pain.,psychiatry the management of severe agitation, hyperactivity, or aggressiveness in psychotic disorders, including schizophrenic reaction and the manic type of manic depressive illness, or in disturbed states, such as some types of acute brain syndrome and in nonpsychotic acute excitation states.

Australia - English - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - erythromycin lactobionate, quantity: 1.49 g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin panpharma (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin

Australia - English - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - hydrocortisone sodium succinate, quantity: 133.7 mg - injection, powder for - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate - when oral therapy is not feasible, and the strength, form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, hydrocortisone panpharma powder for injection is indicated for intravenous or intramuscular use in the following conditions:,1. endocrine disorders ? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements may be necessary, particularly when synthetic analogues are used). ? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful ? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected ? cong

Philippines - English - FDA (Food And Drug Administration)

panpharma-meinz pharmaceuticals corp. - cefuroxime (as axetil) - granules for suspension - 250mg/ 5ml